Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

Against the trial’s posted results

• Same as the trial’s posted resultThis paper HR 0.80 (0.72–0.90)Posted, primary outcome HR 0.80 (0.72–0.89), p < 0.0001Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke